Anita Dushyanth

Jeff Cohen

Jeffrey Cohen

- SINTX Technologies announced the publication of a peer-reviewed study demonstrating that its silicon nitride material exhibits **potent antiviral activity** against multiple infectious virus strains, including SARS-CoV-2 and MERS-CoV.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_0]** 
- This breakthrough opens doors to a wide range of infection-control applications, such as **wound dressings, surgical sutures, face masks, hospital linens, and HEPA filters**.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_0]** 
- The global infection-prevention and control market is projected to exceed **$230 billion by 2032**, with the antiviral PPE market alone estimated to reach **$40+ billion by 2030**.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_1]** 
- SINTX is uniquely positioned as the **only U.S.-based FDA-cleared and ISO-certified silicon nitride manufacturer** to commercialize this technology.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_1]** 
- The company is strategically transitioning from an orthopedic implant manufacturer to a platform technology company, actively pursuing partnerships and licensing opportunities to accelerate commercialization.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_1]**

Sintx Technologies (SINT)